Navigation Links
Amicus Therapeutics Announces Third Quarter 2008 Financial Results
Date:11/3/2008

luted $(0.46) $(0.36) $(2.92) $(1.12)

Weighted-

average

common

shares

outstanding -

basic and

diluted 22,291,832 22,517,431 10,177,449 22,465,981

Table 2

Amicus Therapeutics, Inc.

Reconciliation of GAAP to non-GAAP Measures for the
Statement of Operations Information for Three Months Ended September 30, 2008
(Unaudited)

(In thousands, except share and per share amounts)

Stock GAAP as

Non-GAAP Compensation Reported

Income Statement

Classifications:

Revenue $3,653 $3,653

Research and

development (7,597) $(603) (8,200)

General and

administrative (3,358) (1,013) (4,371)

Depreciation and

amortization (382) (382)

Interest income 1,019 1,019

Interest expense (49) (49)

(Provision

for)/benefit from

income taxes 150 150

Summary:

Net loss: $(6,564) $(1,616) $(8,180)

Net loss per share -

basic and diluted: $(0.29) $(0.07) $(0.36)

Weighted average

number of shares

outstanding: 22,517,431 22,517,431

Table 3

Amicus Therapeutics, Inc.

Reconciliation of GAAP to non-GAAP Measures for the
Statement of Operations Information for Three Months Ended September 30, 2007

'/>"/>

SOURCE Amicus Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Amicus Therapeutics Announces Third Quarter 2008 Results Release Date
2. Amicus Therapeutics to Present at the 2008 UBS Global Life Sciences Conference
3. Amicus Therapeutics Opens Research Facility in San Diego
4. Amicus Therapeutics to Present at the 2008 BioCentury NewsMakers in the Biotech Industry Conference
5. Amicus Therapeutics Announces Second Quarter 2008 Results Release Date
6. Amicus Therapeutics Announces First Quarter 2008 Financial Results
7. Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference
8. Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
9. Amicus Therapeutics to Present at the BIO CEO & Investor Conference 2008
10. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
11. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... ... 2015 , ... Students and faculty from Beijing City University ... “Integrative Biotechnology,” an applied biotechnology course team-taught by faculty members from both institutions. ... from both universities and is taught on both continents. , “Our alliance with ...
(Date:6/30/2015)... June 30, 2015  Today, Americord Registry, one of the ... Andrew Horne , a partner at Kirkland & Ellis LLP, ... Logo - http://photos.prnewswire.com/prnh/20150630/226958LOGO   "We are ... Board," says Martin Smithmyer , CEO of Americord. "He ... career that will assist Americord,s growth and vision." ...
(Date:6/30/2015)... ... June 30, 2015 , ... Matrix Marketing Group, LLC , ... hired Gem Swartz to head up its account management department as vice president of ... and Amanda bring senior account management and delivery expertise to the growing Matrix Marketing ...
(Date:6/30/2015)... IL (PRWEB) , ... June 30, 2015 , ... ... effective August 14. She has accepted the position of vice president of instruction ... August 17. , “I greatly appreciated the opportunity to lead SIUE during ...
Breaking Biology Technology:Rivier University and Beijing City University Academic and Cultural Exchanges Begin 2Americord Registry Announces Andrew Horne as Advisory Board Member 2Matrix Marketing Group Expands Client Services Team 2SIUE’s Furst-Bowe Accepts VP of Instruction at CVTC 2SIUE’s Furst-Bowe Accepts VP of Instruction at CVTC 3
... Heritage has recently,overcome patent claims held by a competitor ... and databases that allow families around,the world to match ... the,use of surnames and Y-chromosomes to establish a family ... rendered a formal opinion,stating that the relevant claims are ...
... of advanced neuromodulation products designed to accelerate recovery from central ... largest provider of inpatient rehabilitative healthcare services, will expand the ... NESS L300™ Foot Drop System to 88 rehabilitation hospitals nationwide. ... ...
... OSAKA, Japan, July 30 /PRNewswire/ - Cytochroma and,Mitsubishi ... have signed a license agreement under which Cytochroma ... Asia, including Japan, to develop,and commercialize CTA018, Cytochroma,s ... development in Canada for the treatment of secondary,hyperparathyroidism ...
Cached Biology Technology:DNA Heritage Success in Patent Battle Helps Keep Genealogy DNA Test Prices Low 2 Bioness Announces NESS H200 and L300 Systems to Be Available at 88 HealthSouth Hospitals Nationwide 2 Bioness Announces NESS H200 and L300 Systems to Be Available at 88 HealthSouth Hospitals Nationwide 3Cytochroma and Mitsubishi Tanabe form partnership for chronic kidney disease therapies in U.S. and Asia 2Cytochroma and Mitsubishi Tanabe form partnership for chronic kidney disease therapies in U.S. and Asia 3Cytochroma and Mitsubishi Tanabe form partnership for chronic kidney disease therapies in U.S. and Asia 4
(Date:6/25/2015)... -- According to a new market ... Technology, Material (Optical Prism, Piezoelectric, Capacitive & Adhesives), ... & Geography - Global Forecast to 2014 - ... expected to reach $14,500.07 Million by 2020, at ... 76 market Tables and 109 Figures spread through ...
(Date:6/25/2015)... , June 25, 2015  TAKE Solutions Ltd., a ... by the United States Patent and Trademark Office (USPTO) ... process leverages TAKE Solutions, Clinical Accelerators to reduce the ... (when compared to standardization without the accelerators), thus reducing ... At the heart of the patented ...
(Date:6/24/2015)... 24, 2015 This report provides market analysis ... six years. It contains an analysis of the drivers, ... their impact from the short, medium, and long term ... industry, market, and technology trends that currently, prevail in ... concerned authorities to efficiently manage the increasing marine traffic ...
Breaking Biology News(10 mins):Fingerprint Sensors Market Worth $14,500.07 Million by 2020 2Fingerprint Sensors Market Worth $14,500.07 Million by 2020 3Fingerprint Sensors Market Worth $14,500.07 Million by 2020 4TAKE Solutions Awarded Patent By USPTO 2Automatic Identification System Market by Class, by Platform, by Application and by Geography - Global Forecasts & Analysis to 2014 - 2020 2
... that are linked with the onset of Barrett,s oesophagus (BE), ... have been identified for the first time. The discovery of ... develop screening tests for people at high risk of developing ... that there may be genetic causes for BE as well ...
... Sunday, September 9, 2012 A new paper published online ... the second most common type of lung cancer may one ... other lung cancer patients. Squamous cell lung cancer ... cancer, ranking second only to lung adenocarcinoma in the number ...
... 7, 2012 The University of Illinois at ... teams joining the NASA Astrobiology Institute (NAI) to study the ... approximately $8 million. Nigel Goldenfeld, Swanlund Professor of ... Institute for Genomic Biology (IGB), will serve as the principal ...
Cached Biology News:Researchers find first evidence for a genetic cause for Barrett's oesophagus 2Researchers find first evidence for a genetic cause for Barrett's oesophagus 3New potential targets discovered for treating squamous cell lung cancers 2New potential targets discovered for treating squamous cell lung cancers 3University of Illinois at Urbana-Champaign awarded 5-year grant from NASA 2University of Illinois at Urbana-Champaign awarded 5-year grant from NASA 3